The Japan autoimmune disease diagnostics market was valued at USD 383.75 million in 2025 and is projected to reach approximately USD 733.99 million by 2035, growing at a robust CAGR of 6.70%. This growth is driven by advancements in diagnostic technologies and increasing autoimmune disease awareness.

Japan Autoimmune Disease Diagnostics Market Statical Scope

Due to rising autoimmune disorder cases, an aging population, better awareness and increasing demand for early detection, advances in immune assays, molecular testing and AI-supported diagnostics are also supporting market expansion.

It is advancing through multiplex immune assays, chemiluminescence systems, molecular testing and Artificial Intelligence -assisted analytics. These technologies improve sensitivity, faster turnaround and simultaneous detection for multiple biomarkers , automation in laboratory digital data integration and collaborations between research institutes and diagnostics firms are also supporting preseason diagnosis and earlier disease identification.

Japan Autoimmune Disease Diagnostics Market Share, By Type, 2025 (%)

• Systemic autoimmune disease diagnostics- The segment dominated the market with a 66% share, due to rising cases of rheumatoid arthritis, lupus and related disorders which require repeated testing, early detection and continuous monitoring through advanced diagnostics panels.
• Localized autoimmune disease diagnostics- The segment accounted for 34% of the total market share, because type one diabetes and thyroid disorders that are common in Japan requiring targeted tests for organ-specific antibodies and early accurate diagnosis for better disease management.

Japan Autoimmune Disease Diagnostics Market Share, By Product, 2025 (%)

• Instruments- The segment accounted for 40% of the total market share, due to higher adoption of advanced analyzers automation and high throughput systems that enable accurate, fast and large-scale testing in clinical laboratories.
• Consumables & Assays- The segment dominated the market with a 60% share, because they are frequently used in repeated testing to ensure high accuracy Support diverse biomarker detection and are essential for routine laboratory workflows.

Japan Autoimmune Disease Diagnostics Market Share, By Test Type, 2025 (%)

• Antinuclear Antibody Tests- The segment dominated the market with a 43% share, because they are widely used as first line screening tools helping detect multiple autoimmune disorders early with high sensitivity and clinical reliability.
• Autoantibody Tests- The segment accounted for 15% of the total market share, because they are usually performed for a specific confirmation after initial screening, making them more targeted diseases specific disease and less frequently used than the broad ANA test.
• C-Reactive Protein (CRP)- The segment accounted for 12% of the total market share, because they are mainly used for major inflammation levels rather than directly diagnose autoimmune diseases, making them supportive rather than primary diagnostic tools.

Japan Autoimmune Disease Diagnostics Market Share, By End Use, 2025 (%)

• Hospitals- The segment dominated the market with a 54% share, because they offer quick, cost-effective and accessible testing services that handle high sample volumes and are increasingly preferred for routine autoimmune screening and follow-up tests.
• Diagnostic centers- The segment accounted for 30% of the total market share, because they offer quick, cost-effective and accessible testing services that handle high sample volume and are increasingly preferred for routine autoimmune screening and follow-up tests.
• Others- The segment accounted for 16% of the total market share, because it includes research institutes and specialty labs in which limited patient volume mainly focused on niche testing and academic or clinical studies.

Top Companies in the Japan Autoimmune Disease Diagnostics Market

• Fujirebio
• Medical & Biological Laboratories (MBL)
• Bio-Rad Laboratories, Inc.
• Abbott
• F. Hoffmann-La Roche, Ltd.
• Siemens Healthineers AG
• Sysmex Corporation
• BioMérieux
• Beckman Coulter ( Danaher)
• SEKISUI MEDICAL CO., LTD

Segments Covered in the Report

By Type

• Systemic autoimmune disease diagnostics
  • Rheumatoid arthritis
  • Ankylosing spondylitis diagnostics
  • Systemic lupus erythematosus (SLE)
  • Others
• Localized autoimmune disease diagnostics
  • Multiple sclerosis
  • Type 1 diabetes
  • Hashimoto's Thyroiditis
  • Idiopathic thrombocytopenic purpura
  • Others

By Product

• Instruments
• Consumables & Assays

By Test Type

• Antinuclear antibody tests
  • Indirect Immunofluorescence (IIF) ANA tests
  • ELISA-based ANA tests
  • Multiplex/line immunoassay ANA panels
  • Others
• Autoantibody tests
  • Rheumatoid Factor (RF) tests
  • Anti-Cyclic Citrullinated Peptide (Anti-CCP) tests
  • Anti-dsDNA tests
  • Anti-Smith (Sm) antibody tests
  • Anti-Ro/SSA & Anti-La/SSB antibody tests
  • Others
• C-reactive Protein (CRP)
• Complete blood count (CBC)
• Urinalysis
• Others

By End Use

• Hospitals
• Diagnostic Centers
• Others